Polymyxin B

CHEMBL5314354 Phase 4 已批准 Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Polymyxin B is a cyclic lipopeptide antibiotic of the polymyxin class that disrupts the integrity of the bacterial outer membrane of Gram-negative bacteria by binding to lipopolysaccharide and displacing calcium and magnesium ions, increasing membrane permeability and causing bactericidal cell death. It is used for the treatment of serious infections caused by multidrug-resistant Gram-negative organisms, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, often as a last-resort antibiotic.

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Polymyxin B is a cyclic lipopeptide antibiotic of the polymyxin class that disrupts the integrity of the bacterial outer membrane of Gram-negative bacteria by binding to lipopolysaccharide and displacing calcium and magnesium ions, increasing membrane permeability and causing bactericidal cell death. It is used for the treatment of serious infections caused by multidrug-resistant Gram-negative organisms, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, often as a last-resort antibiotic.

Yes, Polymyxin B is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314354. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.